All In Biotech

Free tool

FAERS Monitor: Durezol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

Reports naming NDA 022212 or its brand name (Durezol, Difluprednate). Reports on generic versions are filed under their own applications.

Reports

3,862

Serious

1,778

46% of reports

Hospitalization

649

Death reported

126

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

Nothing to show.

Reports by year received

View as table
YearReports
20041
20051
20063
20076
20085
20096
20109
201129
201252
201368
201480
2015169
2016533
2017578
2018355
2019402
2020338
2021243
2022236
2023256
2024191
2025177
2026124

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,297 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.